<DOC>
	<DOCNO>NCT02962141</DOCNO>
	<brief_summary>To evaluate safety efficacy Paclitaxel Releasing Peripheral Balloon Dilatation Catheter ( APERTO OTW ) compare Balloon Dilatation catheter ( OHICHO II ) treatment Arteriovenous Fistulae Stenosis patient undergoing hemodialysis .</brief_summary>
	<brief_title>APERTO OTW Treatment Arteriovenous Fistulae Stenosis Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>To evaluate safety efficacy Paclitaxel Releasing Peripheral Balloon Dilatation Catheter ( APERTO OTW ) compare Balloon Dilatation catheter ( OHICHO II ) treatment Arteriovenous Fistulae Stenosis patient undergoing hemodialysis . This prospective , multi-center , randomize control , open-label , superiority study . A total 160 subject enrol 10 site China . All subject enrol randomly assign test group ( APERTO group , n=80 ) control group ( OHICHO II group , n=80 ) randomize allocation ratio 1:1 . Subjects test group control group treat APERTO OTW OHICHO II respectively .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Patients must meet following criterion : Age ≥ 18 year ≤ 75 year , male female . Patient legally authorize representative understand purpose clinic trial . He She volunteer participate trial provide write informed consent , willing accept schedule followup specific time point . Angiography , ultrasound clinical diagnosis show patient hemodialysis access dysfunction due stenosis lesion . Patients indication percutaneous endovascular therapy , , AVF stenosis relate hemodynamics ≥ 50 % , follow clinical physiological abnormality ( refer NKFK/DOQI guideline definition ) : 1 . Thrombosis AVF ; 2 . Elevated venous pressure dialysis 3 . Obvious abnormality recirculation measurement 4 . Abnormal physical examination finding 5 . Unexplained decrease dialysis dose 6 . Decreased access flow Target lesion de novo restenosis . The number target lesion 1 . Target lesion consist single lesion multiple lesion target lesion length ≤ 40 mm . Target lesion ( ) locate reflux vein anastomosis native arteriovenous fistula ( AVF ) distal end subclavian vein , except anastomosis native AVF . If patient nontarget lesion , must successfully treat use PTA treat target lesion . Reference vessel diameter target lesion ≥ 4.0 mm ≤ 7.0 mm visual estimate ( determined angiography DUS ) . Hemodialysis access previously use ( mature AVF ) longer successfully use due insufficient shunt flow volume cause local lumen stenosis . Exclusion criterion : Patients exclude follow condition applies : Patients participate another investigational drug device trial . Patients enrol trial previously . Women childbearing age negative pregnancy test procedure , breastfeed woman . Any major surgical procedure ( thoracotomy , craniotomy , etc . ) within 30 day prior procedure . Any planned major surgical procedure ( thoracotomy , craniotomy , etc . ) within 30 day entry study Immature AVF , use Dialysis use successfully due insufficient lumen diameter ensure successfully puncture insufficient shunt flow volume . Patients AVG . AVF previously implant stent . Lesion AVF previously treat DEB . Target lesion locate anastomosis native AVF . Known allergy intolerance Paclitaxel contrast medium . Life expectancy &lt; 1 year Patients comitans systemic lupus erythematosus ANCA associate vasculitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>drug elute balloon , Arteriovenous Fistulae</keyword>
</DOC>